Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
about
Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitisCirculating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitisClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabTumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?Clinical Tools to Assess and Monitor SpondyloarthritisIntegrative structural biomechanical concepts of ankylosing spondylitisNew population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.Effectiveness of massage therapy for subacute low-back pain: a randomized controlled trialWhole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey.Alendronate Effect on the Prevention of Bone loss in Early Stages of Ankylosing Spondylitis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordiiPsychological correlates of self-reported functional limitation in patients with ankylosing spondylitis.Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study.Spondyloarthritides: evolving therapiesEffects of glossopharyngeal insufflation in ankylosing spondylitis: a pilot studyShort term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practiceLow bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathiesEfficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trialEffects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow upDevelopment and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.Health status of patients with ankylosing spondylitis: a comparison with the general population.Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?Psoriatic arthritis assessment tools in clinical trials.Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabExpanding the armamentarium for the spondyloarthropathies.The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitisThe epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
P2860
Q24797697-6AD1FCD6-513F-494E-83EE-C50ABCA0A4A7Q24800177-16478D63-7EAA-4C3E-8E55-5EA9BDD201F6Q24816557-0FF176E0-3107-447B-A932-E149497EFD2AQ24816905-A5666F31-FF96-42E7-992E-A5EE71546FE9Q26777908-7F56005E-766B-4C86-8984-7D184D210E00Q26866120-39E6CB27-9CA9-4D7B-ADEA-C442F6629699Q28395076-2E3458BF-56FF-4E90-8D3B-DEFCDD5B47F9Q30586397-5BDDA90A-8F25-49A1-AD7C-812E61FC9113Q31793579-0FF9FF32-B5B7-46F2-9155-35BD40433FEBQ33275865-A63A79BA-35C5-4765-A1EA-EE28FA10A11CQ33766318-6443CD01-1D44-40B3-ACA0-7B83B85590B2Q33883662-537A06DC-3D26-4435-A45F-31F471CAB099Q33918294-1B53B00B-6AB3-4492-A05D-77B9C4CCD0DEQ33993099-B11B6362-7E30-45AE-8844-198A0EA86161Q34014598-94717CBC-A8EE-4891-A7DC-C440494DFF75Q34413304-6DD37A6C-BD03-465C-8E2C-A5C45B0AA7C5Q34425497-86E9F51B-BF2B-4A9E-86EC-FE801E7548F9Q34449888-1C0135E7-ABEF-41F2-9A59-DB88EFF44FBEQ34457833-F9F624C1-E8D0-4B20-9C18-B7117D4DDC33Q34613907-E9FB83C4-5E59-4D7E-AACD-F634835B9CC5Q34650355-9C512993-841E-43BC-BDC6-04527BA592C2Q34708922-1B811886-4B92-4229-839E-BAD823FDD46EQ34709526-16D82DCF-38A2-4B2D-86DC-1382CDF0E7B9Q34758808-8B9D8543-E654-48E6-B473-AB1DB78E63B8Q35194568-33A4383B-6195-46C8-8F06-0A453D69CD5EQ35549397-412D28CC-5809-4877-BBE9-32AA4616BCA5Q35551412-06FCA6C4-54D2-4A3F-92AF-E76410E43EC1Q35553458-C8B533AE-F4F3-48E7-ADCC-95FA2DACFA89Q35553676-AA082287-2B58-45A1-8A40-347E5EF4256BQ35554218-DECC1CF7-32C3-4A4F-854F-5C3111BB86A3Q35555146-9BB0884F-75F5-4BBA-A53A-FBD98680C25DQ35555802-0F9ECB4C-C060-4671-91D0-26791E996215Q35579462-FCA950AD-2FA4-49F0-A6F3-B90EDCB95981Q35637105-66AD11FF-3D6A-427E-A5A0-AB01DFB48D48Q35755789-E7778A72-FC7B-4A56-B4DA-9BE515CEBD3DQ35759171-D27341D2-66CF-44B7-992C-18D82921D159Q35823657-61438300-EE1C-4A30-9F52-92F2FCF50BBFQ35838797-56F3F023-13F2-4180-A084-C40C33FFF75BQ35953484-C0B2B3D2-5A34-405C-8AB7-4E3772E5FB0DQ35953515-F5CA62E7-DBC0-4917-B37A-801B9949031B
P2860
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
@en
Defining spinal mobility in ankylosing spondylitis
@nl
type
label
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
@en
Defining spinal mobility in ankylosing spondylitis
@nl
prefLabel
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
@en
Defining spinal mobility in ankylosing spondylitis
@nl
P2093
P1476
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
@en
P2093
Garrett SL
Jenkinson TR
Kennedy LG
Mallorie PA
Whitelock HC
P304
P407
P577
1994-09-01T00:00:00Z